All In Biotech

Drug Trial Radar · NCT03767244

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 2,517 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

2,517

Actual

Start

Jun 11, 2019

Primary completion

Dec 1, 2026

Study completion Oct 13, 2028

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Dec 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and metastasis-free survival (MFS) as compared to placebo plus ADT.

Conditions

  • Prostatic Neoplasms

Interventions

  • ApalutamideDrug

    Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) orally once daily.

  • Androgen Deprivation Therapy (ADT)Drug

    Participants will receive a stable regimen of ADT - gonadotropin-releasing hormone analog (agonist or antagonist) (GnRHa). ADT is a kind of hormone therapy for prostate cancer. GnRHa will be administrated to achieve and maintain sub-castrate concentrations of testosterone (50 nanogram per deciliter \[ng/dL\]).

  • PlaceboDrug

    Participants will receive matching placebo oral tablets daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Pathologic complete response (pCR)Time frame: Approximately 4 years
  2. Metastasis-Free Survival (MFS)Time frame: Up to 7 years and 5 months

Locations

203 sites in 18 countries. Site status is shown where the registry gives one.

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • University of Southern California

    Los Angeles, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • University of California Los Angeles

    Los Angeles, California

  • University of California Irvine Medical Center Chao Family Comprehensive Cancer Center

    Orange, California

  • UC Davis Medical Center

    Sacramento, California

  • AdventHealth Medical Group Urology of Denver

    Denver, Colorado

  • Colorado Clinical Research

    Lakewood, Colorado

  • Stamford Hospital

    Stamford, Connecticut

  • Urology Specialists LLC

    Hialeah, Florida

  • Mayo Clinic - Division Of Hematology/oncology

    Jacksonville, Florida

  • Miami Cancer Institute at Baptist Health / Baptist Health Medical Group

    Miami, Florida

  • Advent Health

    Orlando, Florida

  • Emory University Winship Cancer Institute

    Atlanta, Georgia

  • University of Chicago

    Chicago, Illinois

  • Ochsner LSU Health Shreveport - Regional Urology

    Shreveport, Louisiana

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Beth Isreal Deaconess Medical Center

    Boston, Massachusetts

  • Michigan Institute of Urology, PC

    Troy, Michigan

  • Saint Louis University

    St Louis, Missouri

  • Urology Cancer Center, PC

    Omaha, Nebraska

  • Albany Medical College

    Albany, New York

  • Great Lakes Physician PC d/b/a Western New York Urology Associates

    Cheektowaga, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Weill Cornell Medical College

    New York, New York

  • SUNY Upstate Medical University

    Syracuse, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Duke University School of Medicine

    Durham, North Carolina

  • Medication Management LLC

    Greensboro, North Carolina

  • Carolina Urology Partners, PLLC

    Huntersville, North Carolina

  • Cleveland VA Medical Center

    Cleveland, Ohio

  • Oklahoma City VAMC

    Oklahoma City, Oklahoma

  • MidLantic Urology

    Bala-Cynwyd, Pennsylvania

  • Omega Medical Research

    Warwick, Rhode Island

  • Ralph H. Johnson Veterans Affairs Medical Center

    Charleston, South Carolina

  • Medical University of South Carolina

    Charleston, South Carolina

  • Greenville Health

    Greenville, South Carolina

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • VA North Texas Health Care System

    Dallas, Texas

Showing 40 of 203 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.